drugset / Trial / NCT05818306
A Phase Ia Safety and Tolerability Study of BL-001
RandomizedParallel-groupTriple-blindHealth-services research
Summary
To investigate the safety and tolerability of BL-001 in healthy volunteers for 28 consecutive days.
Timeline
- Start
- 2023-02-20
- Primary completion
- 2023-05-19
- Completion
- 2023-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BL-001 | Other / unclassified | — | Oral |
Indications
No indication recorded.